{"id":67823,"date":"2026-06-09T23:39:03","date_gmt":"2026-06-09T15:39:03","guid":{"rendered":"https:\/\/flcube.com\/?p=67823"},"modified":"2026-06-09T23:39:04","modified_gmt":"2026-06-09T15:39:04","slug":"jikeshu-sebaloxavir-marboxil-receives-nmpa-approval-for-adolescent-influenza-treatment-expanding-single-dose-category-1-antiviral-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67823","title":{"rendered":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jikeshu<\/strong> (sebaloxavir marboxil), a <strong>Category 1 anti-influenza drug<\/strong> jointly developed by <strong>Jumpcan Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600566:SHA\">SHA: 600566<\/a>) and <strong>Nanjing Zenshine Pharmaceuticals Co., Ltd.<\/strong>, has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>adolescents aged 12 and above<\/strong>, expanding its indication beyond the adult population approved in July 2025.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Jikeshu (sebaloxavir marboxil)<\/td><\/tr><tr><td><strong>Developers<\/strong><\/td><td>Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Adolescents aged 12 and above with influenza<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>July 2025 for previously healthy adults with uncomplicated influenza A and B<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 1 innovative drug (China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-next-generation-influenza-therapy\" class=\"wp-block-heading\">Next-Generation Influenza Therapy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Influenza virus RNA polymerase PA subunit<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Specifically inhibits transcription of viral mRNA, directly intervening in core viral genome replication process<\/li>\n\n\n\n<li><strong>Dosing Regimen<\/strong>: Single oral dose for entire treatment course<\/li>\n\n\n\n<li><strong>Therapeutic Class<\/strong>: First-in-class PA inhibitor with novel mechanism distinct from neuraminidase inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-differentiation\" class=\"wp-block-heading\">Clinical Differentiation<\/h2>\n\n\n\n<h3 id=\"h-single-dose-advantage\" class=\"wp-block-heading\">Single-Dose Advantage<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Simplicity<\/strong>: Complete therapy delivered in one administration<\/li>\n\n\n\n<li><strong>Adherence Guarantee<\/strong>: Eliminates compliance issues associated with multi-day regimens<\/li>\n\n\n\n<li><strong>Rapid Viral Suppression<\/strong>: Early intervention in viral replication cycle<\/li>\n\n\n\n<li><strong>Convenience Factor<\/strong>: Reduces burden on patients, caregivers, and healthcare systems<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-expanded-patient-population\" class=\"wp-block-heading\">Expanded Patient Population<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Age Range<\/strong>: Now covers both adults and adolescents (12+ years)<\/li>\n\n\n\n<li><strong>Influenza Types<\/strong>: Effective against both influenza A and B strains<\/li>\n\n\n\n<li><strong>Disease Severity<\/strong>: Approved for uncomplicated influenza cases<\/li>\n\n\n\n<li><strong>Market Reach<\/strong>: Significantly expands addressable patient population in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Expansion<\/strong>: Builds on successful July 2025 adult launch with pediatric\/adolescent extension<\/li>\n\n\n\n<li><strong>Seasonal Preparation<\/strong>: Timely approval ahead of upcoming influenza season<\/li>\n\n\n\n<li><strong>Partnership Success<\/strong>: Validates collaborative development model between Jumpcan and Zenshine<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Leverages existing manufacturing and distribution networks established for adult indication<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Influenza Burden<\/strong>: Annual seasonal outbreaks affect millions of Chinese adolescents and adults<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Limited single-dose antiviral options create significant market opportunity<\/li>\n\n\n\n<li><strong>Category 1 Status<\/strong>: Premium pricing and regulatory exclusivity benefits for innovative drugs<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Differentiated from oseltamivir (Tamiflu) and other neuraminidase inhibitors through novel mechanism and dosing convenience<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including market adoption, competitive dynamics, seasonal influenza patterns, and post-marketing safety surveillance requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2418,15,2419,1527],"class_list":["post-67823","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-jumpcan-pharmaceutical","tag-product-approvals","tag-sha-600566","tag-zenshine-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67823\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise\" \/>\n<meta property=\"og:description\" content=\"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67823\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:39:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:39:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise\",\"datePublished\":\"2026-06-09T15:39:03+00:00\",\"dateModified\":\"2026-06-09T15:39:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Jumpcan Pharmaceutical\",\"Product approvals\",\"SHA: 600566\",\"Zenshine Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67823#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67823\",\"name\":\"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:39:03+00:00\",\"dateModified\":\"2026-06-09T15:39:04+00:00\",\"description\":\"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67823\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67823#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67823","og_locale":"en_US","og_type":"article","og_title":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise","og_description":"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.","og_url":"https:\/\/flcube.com\/?p=67823","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:39:03+00:00","article_modified_time":"2026-06-09T15:39:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67823#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67823"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise","datePublished":"2026-06-09T15:39:03+00:00","dateModified":"2026-06-09T15:39:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67823"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Jumpcan Pharmaceutical","Product approvals","SHA: 600566","Zenshine Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67823#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67823","url":"https:\/\/flcube.com\/?p=67823","name":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:39:03+00:00","dateModified":"2026-06-09T15:39:04+00:00","description":"Jikeshu (sebaloxavir marboxil), a Category 1 anti-influenza drug jointly developed by Jumpcan Pharmaceutical (SHA: 600566) and Nanjing Zenshine Pharmaceuticals Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) for the treatment of adolescents aged 12 and above, expanding its indication beyond the adult population approved in July 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67823#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67823"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67823#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67823"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67823\/revisions"}],"predecessor-version":[{"id":67824,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67823\/revisions\/67824"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}